Par Mahadevia MD

Senior Global Medical Affairs Leader, Lung Cancer, at Janssen Oncology. Views expressed are my own, not those of Janssen, J&J. RTs are not endorsements.

[Sooners Insider @SoonersInsider]

One thing I know for sure. Plays like this will absolutely win the hearts of Sooner Nation. The dude has guts

#OUDNA

[Mark Wildgust (he/him) @MAWildgust]

So excited to share the #COCOON study met its primary endpoint. Thank you @jillfeldman4 & thank you to all the investigators and most importantly the patients who made this study possible. To my @JNJInnovMed team, you were amazing! #My Company

https://t.co/5fN1cLmBp0

[Par Mahadevia MD @par_onc]

@JoshuaBRobbins What are the specific development priorities for Sarr defensively?

[Mark Wildgust (he/him) @MAWildgust]

RYBREVANT® marketing application submitted to European Medicines Agency based on PALOMA-3 study. #MyCompany

https://t.co/1Gk9AujCPM

[Mark Wildgust (he/him) @MAWildgust]

With my amazing lung cancer oncology global medical affairs @JNJInnovMed team here at #ASCO24, including @JuIianKam who just joined the team! #MyCompany

[OncoAlert @OncoAlert]

The #OncoAlertTopTweet 🚨Day 1 #ASCO24
by @DrSanjayPopat

Subgroup analysis in MARIPOSA1: consistent benefit in all subgroups

#OncoAlertAF
@nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1
@yekeduz_emre @HHorinouchi @FadiHaddad_MD
@Dr_Ivanoncologo @Abdallah81MD @FernandoOnco
@ElisaAgostinett @dr_yakupergun @to_be_elizabeth @anmwongNZ @lungoncdoc

[Gʀᴇɢᴏʀʏ Rɪᴇʟʏ @RielyMD]

My colleague Helena Yu presented @MSK_DeptOfMed @MSKCancerCenter investigator-initiated clinical trial of amivantamab + lazertinib in patients with EGFR mutations AND brain mets Or leptomeningeal disease. Enrolled 42 patients in 24 months #ASCO24 #lcsm

[Mark Wildgust (he/him) @MAWildgust]

Love the butterfly theme here at #ELCC24 . Very much a favorite of mine! #MyCompany

[Ben Solomon @bensolomon1]

Congratulations to the dynamic duo @DanSteinfort and @_ShankarSiva on publication of the SEISMIC study showing the importance of systematic mediastinal node sampling in patients with early stage and locally advanced NSCLC @LancetRespirMed 👏🏽👏🏽

[Par Mahadevia MD @par_onc]

@deeptibehl1 Happy Diwali!

[Par Mahadevia MD @par_onc]

@AngelQinMD Congrats Angel!

[J&J Innovative Medicine Global Medical Affairs @JJ_IMMedAffairs]

For US #HCPs: the Phase 2 COCOON study (NCT06120140) in patients with locally advanced or metastatic EGFR-mutated non-small cell #LungCancer is now on https://t.co/bXtWtKCB9D.

[Mark Wildgust (he/him) @MAWildgust]

Excited to be leading a 2-day symposium here @JNJInnovMed within our incredible organization. As scientists and researchers we will be sharing and discussing the amazing research in Oncology we are leading but also how we continue to innovate in improve care! #MyCompany

[Par Mahadevia MD @par_onc]

@HosseinBorghaei @StephenVLiu @myESMO Ha ha ha, too good!

[Par Mahadevia MD @par_onc]

ESMO presidential plenary-exciting data on lung, breast and prostate cancer. #ESMO2023 #MyCompany

[Mark Wildgust (he/him) @MAWildgust]

Presidential #ESMO23 speakers! #Mariposa and #Mariposa2 butterflies @APassaroMD and Dr Cho! Time to fly. #NSCLC #EGFR #MyCompany

[NEJM @NEJM]

Presented at #ESMO23:

The addition of amivantamab to chemotherapy in patients with advanced non–small-cell lung cancer with EGFR exon 20 insertions resulted in significantly longer progression-free survival.

Full results of the phase 3 PAPILLON trial: https://t.co/wEeOGpV5Wu

[J&J Innovative Medicine Global Medical Affairs @JJ_IMMedAffairs]

For US #HCPs at #ESMO23: see Dr. Nicolas Girard (@nicogirardcurie) present primary results from the Phase 3 PAPILLON study in patients with EGFR exon 20 insertion-mutated advanced non-small cell #LungCancer.

[Par Mahadevia MD @par_onc]

Excited to be at ESMO. Saturday Presidential Plenary starting. PAPILLON Phase 3 study of amivantamab-chemotherapy vs. chemotherapy in 1L EGFR Exon-20 Insertion Advanced NSCLC will be presented. Simultaneous publication at New England Journal of Medicine #ESMO #MyCompany

[Stephen V Liu, MD @StephenVLiu]

#WCLC21 Amivantamab in METex14 NSCLC with RR 64% (5 confirmed, 4 not yet confirmed) including activity post #MET TKI therapy. Time to response 4.1 months. Interesting that one response occurred late on the spider plot. 11/14 still on therapy.